DrugDashboards

Phenobarbital Oral Solution

Phenobarbital Oral · PHENOBARBITAL 20 mg/5mL · Solution · Oral · PAI Holdings, LLC dba PAI Pharma

NDC 00121-0942-50 · 5 TRAY in 1 CASE / 10 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE · UNAPPROVED DRUG OTHER · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00121-0942-16) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.0919per unit
middle half $0.0718$0.1390 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $0.0919
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 4 · prior auth 50% · step therapy 0% · qty limit 54%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$154.25
Reported to Texas DSHS · 2026 annual filing · PAI Holdings LLC dba Pharmaceutical Associates, Inc. / PAI Pharma

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for phenobarbital (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Phenobarbital Oral (Solution)

LabelerStrengthFirst seenLast seen
Kesin Pharma CorporationPHENOBARBITAL 20 mg/5mLJul 15, 2026Sep 3, 2026
Ajenat Pharmaceuticals LLCPHENOBARBITAL 20 mg/5mLJul 15, 2026Sep 2, 2026
BPI Labs LLCPHENOBARBITAL 20 mg/5mLJul 15, 2026Sep 2, 2026
PAI Holdings, LLC dba PAI PharmaPHENOBARBITAL 20 mg/5mLJul 15, 2026Sep 2, 2026
PAI Holdings, LLC dba PAI PharmaPHENOBARBITAL 30 mg/7.5mLJul 15, 2026Sep 2, 2026
PAI Holdings, LLC dba PAI PharmaPHENOBARBITAL 60 mg/15mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Phenobarbital Oral Solution — NDC 00121-0942-50," retrieved September 3, 2026, https://drugdashboards.com/drug/00121094250.

Free to cite with attribution — see how the data is put together.